OTC Watch

All stocks / BCAB

BioAtla, Inc. BCAB

BioAtla (BCAB): financing deals mentioned in an 8-K in October 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.

Costly financingEstimated float OTCQBCalifornia, USA
Live quote on OTC Markets

Market listing

Full name
BIOATLA INC
Market tier
OTCQB
Trading status
Active
Last trade
Nov 16
Source: Stockwatch, 2026-11-17

News headlines

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
2026-05-18 06:45 · News Release
BioAtla Announces Share Consolidation
2026-03-31 16:06 · News Release
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
2026-03-31 16:05 · News Release
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
2026-03-02 07:30 · News Release
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
2025-12-31 07:00 · News Release
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
2025-11-21 00:26 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Net loss
($59,607,000)
What it means

It spends more than it earns

Under strain

The company lost $59.6 million in the year. It reported no sales.

The report says
Cash and cash equivalents
$7,118,000
Net cash used in operating activities
($48,204,000)
What it means

The cash could run out soon

Under strain

It had $7.1 million in the bank and used about $4 million a month. At that pace the money lasts about 2 months unless it borrows or sells more shares.

The report says
Total assets
$13,828,000
Total liabilities
$50,017,000
What it means

It owes more than it owns

Under strain

Everything the company owns adds up to $13.8 million. Its debts and unpaid bills add up to $50 million. That is about $3.62 owed for every $1 owned.

What this adds up to

3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.

Signals

Costly financing2026-10-20

8-K filed 2026-10-20 mentions: equity line.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Estimated float2026-09-30

Estimated float about 1,250,983 shares as of 2026-09-30: 1,668,261 outstanding minus 417,278 held by 4 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Costly financing2026-03-02

8-K filed 2026-03-02 mentions: equity line.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Costly financing2026-02-06

8-K filed 2026-02-06 mentions: equity line.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Costly financing2026-01-30

8-K filed 2026-01-30 mentions: equity line.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Costly financing2026-01-12

8-K filed 2026-01-12 mentions: equity line.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Costly financing2025-12-30

8-K filed 2025-12-30 mentions: equity line.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Costly financing2025-11-21

8-K filed 2025-11-21 mentions: equity line.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Shares outstanding

Source: SEC filings
2024-12-31
1.2M
2025-03-31
58.4M
2025-06-30
58.7M
2025-09-30
58.8M
2025-12-31
1.3M
2026-03-31
1.7M
2026-06-30
1.7M
2026-09-30
1.7M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-16 10-Q10-Q
2026-10-29 424B3424B3
2026-10-29 EFFECT
2026-10-27 RWRW
2026-10-20 8-K8-K
2026-10-20 S-1S-1
2026-09-29 8-K8-K
2026-09-02 44
2026-09-02 44
2026-09-02 44
2026-08-28 8-KFORM 8-K
2026-08-13 10-Q10-Q

Common questions about BCAB

Does BCAB file reports with the SEC?

Yes. BioAtla files with the SEC under company number 0001826892. The most recent filing we hold is a 10-Q dated 2026-11-16.

Source record

How many BCAB shares are outstanding?

1,668,261 shares as of 2026-09-30, as reported to the SEC.

Source record

Has BCAB filed reports late?

We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.

Who runs BioAtla?

Officers named in its insider filings: Jay M Phd Short (Chief Executive Officer), Eric Sievers (Chief Medical Officer) and Christian Vasquez (Chief Financial Officer).

Source record

Is BioAtla making money?

The company lost $59.6 million in the year. It reported no sales. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record